Pfizer, Valneva report Lyme vaccine results

Pfizer and Valneva SE have announced the results from their Phase 3 clinical trial for a Lyme disease vaccine candidate. The trial evaluated the efficacy and safety of the vaccine, VLA15, in preventing Lyme borreliosis. While specific outcomes are detailed in the report, the companies are continuing to assess the data. This development is significant for public health, potentially offering a new tool to combat the tick-borne illness that affects thousands annually. Further regulatory steps will depend on the comprehensive analysis of these trial findings.